Clinical trials: Post Tuberculosis
Hepatitis, Tuberculosis, Pulmonary
Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment
Despite the availability of effective anti-tuberculosis agents that exist to treat this illness, hepatotoxicity during first-line drugs anti-tuberculosis medications (ATT) such as isoniazid (INH), rifampin (RIF), and pyrazinamide…
- Trial name
- NCT01395654
- Testing
- isoniazid, rifampin, pyrazinamide
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Tuberculosis
Tuberculosis Treatment Shortening Trial
Tuberculosis (TB) is a serious infection that can affect the lungs and other parts of the body. The usual way to treat TB is to take 4 medicines by mouth every day for 2 months, then take 2 of the same medicines for 4 more…
- Trial name
- NCT00130247
- Testing
- Ethambutol, Isoniazid, Pyrazinamide
- Where
- 3 sites in Brazil, Philippines and 1 more
- Volunteers
- 394 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dovprela
Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance
Dovprela Tablets (Pretomanid) is the only treatment approved for the treatment of drug-resistant tuberculosis on a wider scale. This non-interventional post-marketing surveillance (PMS) study is one of the obligations that must…
- Trial name
- NCT06471088
- Testing
- Dovprela
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Viatris Inc.
Tuberculosis, Post Tuberculosis
LIFE-TB ; Long-Term Impacts on Lung Health and Life After Tuberculosis in Korea
This is a prospective, multicenter observational cohort study aimed at establishing a nationwide post-TB lung disease registry in Korea.
- Trial name
- NCT06946784
- Where
- South Korea
- Volunteers
- 360 people
- Sponsor
- Yonsei University
Tuberculosis, Skin Tests
Tolerability and Reactogenicity Trial of the Recombinant Tuberculosis Allergen in Healthy Volunteers
Primary objective of the trial is to study the safety and tolerability of the Recombinant tuberculosis allergen in standard dilution in healthy volunteers after a single dose.
- Trial name
- NCT05398562
- Testing
- Mycobacterial recombinant allergens 0.1 μg, Mycobacterial recombinant allergens 0.2 μg
- Where
- Russia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Tuberculosis, Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00810407
- Testing
- rifabutin
- Volunteers
- 628 people
- Sponsor
- Pfizer
Tuberculosis, Pulmonary, Household Contacts
Airborne Preventive Measures to Reduce New TB Infections in Household Contacts
Tuberculosis (TB) is currently one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS).
- Conditions
- Tuberculosis, Pulmonary, Household Contacts, Tuberculosis
- Trial name
- TBMask (NCT04938596)
- Testing
- Respiratory bundle
- Where
- Chile
- Volunteers
- 432 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Tuberculosis
Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PNU-100480 (PF-02341272) after a single dose in healthy adult volunteers.
- Trial name
- NCT00871949
- Testing
- PNU-100480
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Sequella, Inc.
Tuberculosis
Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis
New blood tests have become available to detect either latent or active tuberculosis. These tests - which according to the CDC can replace the tuberculin skin test - measure the production of gamma-interferon (a cytokine) by…
- Trial name
- NCT00595907
- Where
- Switzerland
- Volunteers
- 89 people
- Sponsor
- University Hospital, Geneva
Tuberculosis
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to…
- Trial name
- NCT05547464
- Testing
- BNT164a1, BNT164b1
- Where
- 8 sites in Mozambique, South Africa
- Volunteers
- 497 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Tuberculosis
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers
This randomized, placebo-controlled, double-blind, safety and dose-finding Phase Ia trial will evaluate four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a…
- Trial name
- NCT05537038
- Testing
- BNT164a1, BNT164b1
- Where
- 3 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Tuberculosis, Multidrug Resistant
Safety of RUTI® Vaccination in MDR-TB Patients
Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIa trial to evaluate safety and immunogenicity of RUTI® vaccine in Multidrug-resistant Tuberculosis (MDR-TB) patients favourably responding to…
- Trial name
- NCT02711735
- Testing
- RUTI® Therapeutic vaccine
- Where
- 3 sites in Ukraine
- Volunteers
- 9 people
- Sponsor
- Archivel Farma S.L.
Tuberculosis, Pulmonary
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary…
- Trial name
- Hi-DoRi-3 (NCT04485156)
- Testing
- High-dose rifampicin, Isoniazid, Pyrazinamide
- Where
- South Korea
- Volunteers
- 926 people
- Sponsor
- Seoul National University Hospital
Pulmonary TB
Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
This prospective study aims to determine the incidence of Post-tuberculosis lung damage (PTLD), examine trends in the changes in lung function, and investigate the impact of smoking and other factors on respiratory symptoms, lung…
- Trial name
- NCT05426720
- Testing
- no intervention
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Peking University Third Hospital
Lung Cancer, Tuberculosis (TB)
Effectiveness of Chat-based Mobile Application for Consultation (Zalo) in Improving Compliance With Follow-up Tests After Abnormal Chest X-ray Findings Interpret by Artificial Intelligent
The study titled "Effectiveness of Chat-based Mobile Application for Consultation (Zalo) in Improving Compliance with Follow-up Tests after Abnormal Chest X-ray Findings Interpreted by Artificial Intelligence" aims to evaluate…
- Conditions
- Lung Cancer, Tuberculosis (TB), Chat-based Mobile Application, Compliance Behavior
- Trial name
- NCT07234929
- Testing
- chat-based mobile application (Zalo)
- Where
- Vietnam
- Volunteers
- 2,692 people, healthy volunteers welcome
- Sponsor
- Gia Dinh People Hospital
Hepatitis C, HCV
TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
The purpose of this study is to assess the interactions seen when somebody doses with TMC435350 and Rifampin (commercial form of antibiotic).
- Conditions
- Hepatitis C, HCV, Tuberculosis, Rifampin
- Trial name
- NCT00741169
- Testing
- TMC435350, Rifampin, TMC435350+rifampin
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Tuberculosis
A Study of MVA85A in Healthy Children and Infants
This study is designed to evaluate the safety of the TB vaccine MVA85A in healthy children and infants in South Africa. A single vaccination with MVA85A has been shown to be safe and highly immunogenic in a wide range of subjects…
- Trial name
- NCT00679159
- Testing
- MVA85A, Prevenar
- Where
- South Africa
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Post Tuberculosis
Mechanisms, Biomarkers and Pulmonary Rehabilitation in Post-TB Lung Disease
Tuberculosis (TB) affects millions of people worldwide, and many individuals continue to experience long-term health problems even after completing TB treatment.
- Trial name
- AFTER-TB (NCT07731009)
- Testing
- Pulmonary rehabilitation
- Volunteers
- 760 people
- Sponsor
- Jose Antonio Dominguez Benitez
Tuberculosis, Latent Tuberculosis
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure
- Trial name
- LIMBO-TB (NCT06526689)
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset
Despite marked improvements in the diagnosis of tuberculosis there are difficulties in diagnosing and monitoring treatment outcome among TB patients.
- Trial name
- LILAC-TB (NCT04015713)
- Where
- 2 sites in Cambodia, Côte d’Ivoire
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases